Prostate-specific antigen-based prostate cancer screening: Past and future

International Journal of Urology

Volumn 22, Issue 6, 2015, Pages 524-532

  Alberts, Arnout R ^a   Schoots, Ivo G ^a   Roobol, Monique J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Guidelines; Multiparametric MRI; Prostate cancer; PSA; Risk assessment; Screening

Indexed keywords

KALLIKREIN; PROSTATE SPECIFIC ANTIGEN;

CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER SCREENING; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE MARKER; HUMAN; MALE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT HARM; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); ADVERSE EFFECTS; BIOPSY; BLOOD; EARLY CANCER DIAGNOSIS; PATHOLOGY; PROSTATE; PROSTATIC NEOPLASMS; UNNECESSARY PROCEDURE; WATCHFUL WAITING;

BIOPSY; EARLY DETECTION OF CANCER; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PRACTICE GUIDELINES AS TOPIC; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNNECESSARY PROCEDURES; WATCHFUL WAITING;

EID: 84930376299     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.12750     Document Type: Review

References (117)

1. Ferlay J, Shin H, Bray F et al. GLOBOCAN 2008, Cancer incidence and mortality worldwide: IARC CancerBase No. 10. International Agency for Research on Cancer, Lyon, France, 2010.
2. Society AC. Prostate Cancer, 2012.
3. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur. J. Cancer 2013; 49: 1374-403.
4. Ito K. Prostate cancer in Asian men. Nat. Rev. Urol. 2014; 11: 197-212.
5. Prostate Cancer. Surveillance, Epidemiology, and End Results Program 2014.
6. United Nations DoEaSA, Population Division. World population prospects: the 2008 revision, 2009.
7. Thompson IM, Ankerst DP, Chi C et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0ng/ml or lower. JAMA 2005; 294: 66-70.
8. Ankerst DP, Thompson IM. Sensitivity and specificity of prostate-specific antigen for prostate cancer detection with high rates of biopsy verification. Arch. Ital. Urol. Androl. 2006; 78: 125-9.
9. Catalona WJ, Richie JP, Ahmann FR et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6, 630 men. J. Urol. 1994; 151: 1283-90.
10. Schroder FH, van derMaas P, Beemsterboer P et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J. Natl. Cancer Inst. 1998; 90: 1817-23.
11. Gosselaar C, Kranse R, Roobol MJ, Roemeling S, Schroder FH. The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer. Prostate 2008; 68: 985-93.
12. Edwards BK, Noone AM, Mariotto AB et al. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 2014; 120: 1290-314.
13. Arnold M, Karim-Kos HE, Coebergh JW et al. Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory. Eur. J. Cancer 2014; doi:10.1016/j.ejca.2013.09.002
14. Catalona WJ, Smith DS, Ratliff TL et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N. Engl. J. Med. 1991; 324: 1156-61.
15. Ito K, Kubota Y, Yamamoto T et al. Long term follow-up of mass screening for prostate carcinoma in men with initial prostate specific antigen levels of 4.0ng/ml or less. Cancer 2001; 91: 744-51.
16. Sandblom G, Varenhorst E, Rosell J, Lofman O, Carlsson P. Randomised prostate cancer screening trial: 20year follow-up. BMJ 2011; 342: d1539.
17. Kjellman A, Akre O, Norming U, Tornblom M, Gustafsson O. 15-year followup of a population based prostate cancer screening study. J. Urol. 2009; 181: 1615-21; discussion 21.
18. Labrie F, Candas B, Cusan L et al. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate 2004; 59: 311-8.
19. Oberaigner W, Siebert U, Horninger W et al. Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008. Int. J. Public Health 2012; 57: 57-62.
20. Andriole GL, Crawford ED, Grubb RL3rd et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13years of follow-up. J. Natl. Cancer Inst. 2012; 104: 125-32.
21. Hugosson J, Carlsson S, Aus G et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010; 11: 725-32.
22. Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13years of follow-up. Lancet 2014; 384: 2027-35.
23. Ito K, Yamamoto T, Ohi M et al. Cumulative probability of PSA increase above 4.0 NG/ML in population-based screening for prostate cancer. Int. J. Cancer 2004; 109: 455-60.
24. Sandblom G, Varenhorst E, Lofman O, Rosell J, Carlsson P. Clinical consequences of screening for prostate cancer: 15years follow-up of a randomised controlled trial in Sweden. Eur. Urol. 2004; 46: 717-23; discussion 24.
25. Bartsch G, Horninger W, Klocker H et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001; 58: 417-24.
26. Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 2009; 360: 1320-8.
27. Andriole GL, Crawford ED, Grubb RL3rd et al. Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 2009; 360: 1310-9.
28. Schroder FH, Hugosson J, Roobol MJ et al. Prostate-cancer mortality at 11years of follow-up. N. Engl. J. Med. 2012; 366: 981-90.
29. Grubb RL3rd, Pinsky PF, Greenlee RT et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int. 2008; 102: 1524-30.
30. Etzioni R, Gulati R, Cooperberg MR, Penson DM, Weiss NS, Thompson IM. Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening. Med. Care 2013; 51: 295-300.
31. Heijnsdijk EA, Wever EM, Auvinen A et al. Quality-of-life effects of prostate-specific antigen screening. N. Engl. J. Med. 2012; 367: 595-605.
32. Bokhorst LP, Bangma CH, vanLeenders GJ et al. Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. Eur. Urol. 2014; 65: 329-36.
33. Schroder FH, Roobol MJ. ERSPC and PLCO prostate cancer screening studies: what are the differences? Eur. Urol. 2010; 58: 46-52.
34. Gulati R, Tsodikov A, Wever EM et al. The impact of PLCO control arm contamination on perceived PSA screening efficacy. Cancer Causes Control 2012; 23: 827-35.
35. Etzioni R, Gulati R, Tsodikov A et al. The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer 2012; 118: 5955-63.
36. Djulbegovic M, Beyth RJ, Neuberger MM et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 2010; 341: c4543.
37. Ilic D, O'Connor D, Green S, Wilt TJ. Screening for prostate cancer: an updated Cochrane systematic review. BJU Int. 2011; 107: 882-91.
38. Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst. Rev. 2013; 1: CD004720.
39. Roobol MJ, Carlsson S, Hugosson J. Meta-analysis finds screening for prostate cancer with PSA does not reduce prostate cancer-related or all-cause mortality but results likely due to heterogeneity - the two highest quality studies identified do find prostate cancer-related mortality reductions. Evid. Based Med. 2011; 16: 20-1.
40. Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen MF, Schrder FH. Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology 2002; 60: 826-30.
41. Loeb S, van denHeuvel S, Zhu X, Bangma CH, Schroder FH, Roobol MJ. Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur. Urol. 2012; 61: 1110-4.
42. Macefield RC, Metcalfe C, Lane JA et al. Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result. Br. J. Cancer 2010; 102: 1335-40.
43. Draisma G, Boer R, Otto SJ et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J. Natl. Cancer Inst. 2003; 95: 868-78.
44. Draisma G, Etzioni R, Tsodikov A et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J. Natl. Cancer Inst. 2009; 101: 374-83.
45. Loeb S, Bjurlin MA, Nicholson J et al. Overdiagnosis and overtreatment of prostate cancer. Eur. Urol. 2014; 65: 1046-55.
46. Gulati R, Gore JL, Etzioni R. Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann. Intern. Med. 2013; 158: 145-53.
47. deCarvalho TM, Heijnsdijk EA, deKoning HJ. Screening for prostate cancer in the US? Reduce the harms and keep the benefit. Int. J. Cancer 2014; 136: 1600-7.
48. Ganz PA, Barry JM, Burke W et al. National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer. Ann. Intern. Med. 2012; 156: 591-5.
49. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J. Clin. Oncol. 2010; 28: 126-31.
50. Roobol MJ. International perspectives on screening. Urol. Clin. North Am. 2014; 41: 237-47.
51. Carroll PR, Parsons JK, Andriole G et al. Prostate cancer early detection, version 1.2014. J. Natl. Compr. Canc. Netw. 2014; 12: 1211-9.
52. Carter HB, Albertsen PC, Barry MJ et al. Early detection of prostate cancer: AUA Guideline. J. Urol. 2013; 190: 419-26.
53. Heidenreich A, Abrahamsson PA, Artibani W et al. Early detection of prostate cancer: European Association of Urology recommendation. Eur. Urol. 2013; 64: 347-54.
54. Qaseem A, Barry MJ, Denberg TD, Owens DK, Shekelle P. Clinical Guidelines Committee of the American College of P. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann. Intern. Med. 2013; 158: 761-9.
55. Moyer VA, Force USPST. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 2012; 157: 120-34.
56. Basch E, Oliver TK, Vickers A et al. Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion. J. Clin. Oncol. 2012; 30: 3020-5.
57. Wolf AM, Wender RC, Etzioni RB et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J. Clin. 2010; 60: 70-98.
58. Committee for Establishment of the Guidelines on Screening for Prostate C, Japanese Urological A. Updated Japanese Urological Association Guidelines on prostate-specific antigen-based screening for prostate cancer in 2010. Int. J. Urol. 2010; 17: 830-8.
59. Lim LS, Sherin K, Committee APP. Screening for prostate cancer in U.S. men ACPM position statement on preventive practice. Am. J. Prev. Med. 2008; 34: 164-70.
60. Murphy DG, Ahlering T, Catalona WJ et al. The Melbourne Consensus Statement on the early detection of prostate cancer. BJU Int. 2014; 113: 186-8.
61. Roobol MJ, Schroder FH. The rate of overdiagnosis inextricably linked to prostate-specific antigen-based screening for prostate cancer can be quantified in several ways, but what is the practicable message? Eur. Urol. 2014; 65: 1056-7.
62. Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM. Beyond PSA: the next generation of prostate cancer biomarkers. Sci. Transl. Med. 2012; 4: 127rv3.
63. Goessl C, Muller M, Heicappell R et al. DNA-based detection of prostate cancer in urine after prostatic massage. Urology 2001; 58: 335-8.
64. Woodson K, O'Reilly KJ, Hanson JC, Nelson D, Walk EL, Tangrea JA. The usefulness of the detection of GSTP1 methylation in urine as a biomarker in the diagnosis of prostate cancer. J. Urol. 2008; 179: 508-11; discussion 11-2.
65. Gonzalgo ML, Pavlovich CP, Lee SM, Nelson WG. Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. Clin. Cancer Res. 2003; 9: 2673-7.
66. Christensson A, Bjork T, Nilsson O et al. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J. Urol. 1993; 150: 100-5.
67. Catalona WJ, Partin AW, Slawin KM et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 279: 1542-7.
68. Djavan B, Zlotta A, Kratzik C et al. PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0ng/mL. Urology 1999; 54: 517-22.
69. Djavan B, Zlotta A, Remzi M et al. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1, 051 men. J. Urol. 2000; 163: 1144-8; discussion 8-9.
70. Woodrum DL, Brawer MK, Partin AW, Catalona WJ, Southwick PC. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J. Urol. 1998; 159: 5-12.
71. Djavan B, Remzi M, Schulman CC, Marberger M, Zlotta AR. Repeat prostate biopsy: who, how and when?. a review. Eur. Urol. 2002; 42: 93-103.
72. Khan MA, Sokoll LJ, Chan DW et al. Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%. Urology 2004; 64: 1160-4.
73. Chan TY, Mikolajczyk SD, Lecksell K et al. Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen. Urology 2003; 62: 177-81.
74. Mikolajczyk SD, Millar LS, Wang TJ et al. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res. 2000; 60: 756-9.
75. Sokoll LJ, Wang Y, Feng Z et al. [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J. Urol. 2008; 180: 539-43; discussion 43.
76. Sokoll LJ, Sanda MG, Feng Z et al. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol. Biomarkers Prev. 2010; 19: 1193-200.
77. Le BV, Griffin CR, Loeb S et al. [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J. Urol. 2010; 183: 1355-9.
78. Guazzoni G, Nava L, Lazzeri M et al. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10ng/ml: results of a prospective study in a clinical setting. Eur. Urol. 2011; 60: 214-22.
79. Houlgatte A, Vincendeau S, Desfemmes F et al. [Use of [-2] pro PSA and phi index for early detection of prostate cancer: a prospective of 452 patients] Place du -2proPSA et de l'index phi dans la detection precoce du cancer de prostate: evaluation sur une serie de 452 patients. Prog. Urol. 2012; 22: 279-83.
80. Benchikh A, Savage C, Cronin A et al. A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France. BMC Cancer 2010; 10: 635.
81. Vickers A, Cronin A, Roobol M et al. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J. Clin. Oncol. 2010; 28: 2493-8.
82. Vickers AJ, Gupta A, Savage CJ et al. A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15years without screening. Cancer Epidemiol. Biomarkers Prev. 2011; 20: 255-61.
83. Roobol MJ, vanVugt HA, Loeb S et al. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. Eur. Urol. 2012; 61: 577-83.
84. Zhu X, Albertsen PC, Andriole GL, Roobol MJ, Schroder FH, Vickers AJ. Risk-based prostate cancer screening. Eur. Urol. 2012; 61: 652-61.
85. Kranse R, Roobol M, Schroder FH. A graphical device to represent the outcomes of a logistic regression analysis. Prostate 2008; 68: 1674-80.
86. Roobol MJ, Steyerberg EW, Kranse R et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur. Urol. 2010; 57: 79-85.
87. vanVugt HA, Roobol MJ, Busstra M et al. Compliance with biopsy recommendations of a prostate cancer risk calculator. BJU Int. 2012; 109: 1480-8.
88. vanVugt HA, Kranse R, Steyerberg EW et al. Prospective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort. Eur. J. Cancer 2012; 48: 1809-15.
89. vanVugt HA, Roobol MJ, Kranse R et al. Prediction of prostate cancer in unscreened men: external validation of a risk calculator. Eur. J. Cancer 2011; 47: 903-9.
90. Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J. Urol. 1989; 142: 71-4; discussion 4-5.
91. Eichler K, Hempel S, Wilby J, Myers L, Bachmann LM, Kleijnen J. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J. Urol. 2006; 175: 1605-12.
92. Wright JL, Ellis WJ. Improved prostate cancer detection with anterior apical prostate biopsies. Urol. Oncol. 2006; 24: 492-5.
93. Moussa AS, Meshref A, Schoenfield L et al. Importance of additional extreme anterior apical needle biopsies in the initial detection of prostate cancer. Urology 2010; 75: 1034-9.
94. King CR, McNeal JE, Gill H, Presti JCJr. Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients. Int. J. Radiat. Oncol. Biol. Phys. 2004; 59: 386-91.
95. Zaytoun OM, Moussa AS, Gao T, Fareed K, Jones JS. Office based transrectal saturation biopsy improves prostate cancer detection compared to extended biopsy in the repeat biopsy population. J. Urol. 2011; 186: 850-4.
96. Puech P, Potiron E, Lemaitre L et al. Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens. Urology 2009; 74: 1094-9.
97. Vargas HA, Akin O, Shukla-Dave A et al. Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer: a prospective study. Radiology 2012; 265: 478-87.
98. Villeirs GM, De Meerleer GO, De Visschere PJ, Fonteyne VH, Verbaeys AC, Oosterlinck W. Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: a single-institution experience of 356 patients. Eur. J. Radiol. 2011; 77: 340-5.
99. Pinto PA, Chung PH, Rastinehad AR et al. Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. J. Urol. 2011; 186: 1281-5.
100. Villers A, Lemaitre L, Haffner J, Puech P. Current status of MRI for the diagnosis, staging and prognosis of prostate cancer: implications for focal therapy and active surveillance. Curr. Opin. Urol. 2009; 19: 274-82.
101. Sonn GA, Chang E, Natarajan S et al. Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen. Eur. Urol. 2014; 65: 809-15.
102. Puech P, Rouviere O, Renard-Penna R et al. Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy--prospective multicenter study. Radiology 2013; 268: 461-9.
103. Stephenson SK, Chang EK, Marks LS. Screening and detection advances in magnetic resonance image-guided prostate biopsy. Urol. Clin. North Am. 2014; 41: 315-26.
104. Hadaschik BA, Kuru TH, Tulea C et al. A novel stereotactic prostate biopsy system integrating pre-interventional magnetic resonance imaging and live ultrasound fusion. J. Urol. 2011; 186: 2214-20.
105. Xu S, Kruecker J, Turkbey B et al. Real-time MRI-TRUS fusion for guidance of targeted prostate biopsies. Comput. Aided Surg. 2008; 13: 255-64.
106. Moore CM, Robertson NL, Arsanious N et al. Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur. Urol. 2013; 63: 125-40.
107. Haffner J, Lemaitre L, Puech P et al. Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU Int. 2011; 108: E171-8.
108. Siddiqui MM, Rais-Bahrami S, Truong H et al. Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur. Urol. 2013; 64: 713-9.
109. Pokorny MR, deRooij M, Duncan E et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur. Urol. 2014; 66: 22-9.
110. Schoots IG, Roobol MJ, Nieboer D, Bangma CH, Steyerberg EW, Hunink M. Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: A systematic review and meta-analysis. Eur. Urol. 2014; doi: 10.1016/j.eururo.2014.11.037.
111. Heidenreich A, Bastian PJ, Bellmunt J et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur. Urol. 2014; 65: 124-37.
112. Barentsz JO, Richenberg J, Clements R et al. ESUR prostate MR guidelines 2012. Eur. Radiol. 2012; 22: 746-57.
113. Moore CM, Kasivisvanathan V, Eggener S et al. Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur. Urol. 2013; 64: 544-52.
114. Hambrock T, Hoeks C, Hulsbergen-van de Kaa C et al. Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort. Eur. Urol. 2012; 61: 177-84.
115. Akin O, Gultekin DH, Vargas HA et al. Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results. Eur. Radiol. 2011; 21: 1970-8.
116. Latchamsetty KC, Borden LSJr, Porter CR et al. Experience improves staging accuracy of endorectal magnetic resonance imaging in prostate cancer: what is the learning curve? Can. J. Urol. 2007; 14: 3429-34.
117. Izawa JI, Klotz L, Siemens DR et al. Prostate cancer screening: Canadian guidelines 2011. Can. Eur. Assoc. J. 2011; 5: 235-40.